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INTRODUCTION 
Methotrexate is a folic acid antagonist 
drug which is used in patients with brain 
tumors (Fig 1).
1 
 
 
Figure 1: Chemical structure of methotrexate 
In addition to the clinical use of 
methotrexate; it is the subject of many 
preclinical investigations pertaining to its 
interesting pharmacological properties. One 
area of interest which is pertinent to its use 
in primary central nervous system 
lymphoma (PCNSL) is the cellular 
mechanics that control the uptake and 
accumulation of methotrexate in the central 
nervous system (CNS). 
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ABSTRACT 
Background and aims: A selective and sensitive high performance liquid 
chromatography-electrospray ionization mass spectrometry method has been established 
for determination of methotrexate in human plasma. 
Methods: Methotrexate was extracted from plasma with acetonitrile. The mobile phase 
consisted of acetonitrile-water-formic acid 74: 25: 1(v/v). Twenty µl of sample was 
chromatographically analyzed using a repacked ZORBAX-XDB-ODS C18 column 
(2.1mm×30mm, 3.5 micron). The mode of mass spectrometry was selected-ion 
monitoring (SIM). 
Results: Standard curve was linear (r= 0.998) over the concentration range of 0.1–100.0 
ng/ml and showed a suitable accuracy and precision. The limit of detection (LOD) was 
0.05ng/ml. 
Conclusion: The method is quick, easy, very steady and precise for the partition, 
assignment and evaluation of methotrexate in human plasma. 
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Methotrexate is a substrate for certain 
members of the ABC transporter family, 
which serves as drug efflux pumps that 
can alter methotrexate’s pharmacokinetic 
properties and the associated sensitivity of 
tumor cells.
2–4
 As some of these 
transporters are located on the 
blood‐brain barrier (BBB) and blood 
cerebrospinal fluid barrier (BCSFB), 
barriers that often limit drug accumulation 
in brain, they may also influence 
methotrexate’s CNS accumulation. In 
addition to these anatomic barriers, drug 
efflux pumps also operate in tumor cells 
and may be a contributing factor to a drug 
resistance phenotype by their ability to 
limit access of the drug to the intracellular 
space.
5-7
 
Thus, to facilitate the exploration of 
the determinants of methotrexate’s CNS 
distribution in preclinical tumor models, 
sensitive LC/MS/MS method based on the 
use of small sample volumes was 
developed. As one can appreciate due to 
the longevity of methotrexate as an 
anticancer drug there have been numerous 
HPLC methods to determinate 
methotrexate in biological specimens. 
Most often these methods utilize solid 
phase extraction for sample clean up with 
either UV or derivative fluorescence 
detection.
8-16
 Since most of these methods 
were developed for human samples, 
relatively large volumes [i.e.>0.1 ml] of 
plasma were needed to achieve the desired 
sensitivity limit. There are a limited 
number of methods reported for the 
quantization of methotrexate in preclinical 
samples.
17,18
 
Measurement of MTX in human 
plasma by LC/MS/MS has yielded 
improved sensitivity limits of 0.5 ng/ml, 
based upon a 200µl plasma sample and a 
liquid‐liquid extraction procedure, and 5 
ng/ml, based upon 20 µl plasma and a 
solid‐phase extraction procedure.19,20 
Previously our work was 
determination of drugs by LC–MS and 
HPLC methods in human plasma.
20-24
 In 
the present study, simple, selective and 
stable method using high performance 
liquid chromatography coupled with 
electro spray ionization single quadruple 
mass spectrometry for the determination of 
methotrexate in human plasma is 
described. 
 
METHODS 
Methotrexate standard (99.9% purity) 
was supplied and identified by EBEWE 
pharm. Acetonitrile with HPLC grade was 
purchased from Merck (Merck Company, 
Germany). Other chemicals and solvents 
were from analytical or chemical lab with 
purity grades, as needed, and purchased 
locally. 
Liquid chromatography was carried out 
using a high performance liquid 
chromatography (HPLC) system (Agilent 
Technologies, model LC-1200, Englewood, 
USA) equipped by an auto sampler. The 
analytical column used was a C18 column 
(Company, ZORBAX XDB-ODS, USA) 
(2.19100 mm, 3.5 micron) and was 
operated at 25
o
C. The mobile phase 
consisted of acetonitrile-water-formic acid 
74: 25: 1 (v/v) which was set at a flow rate 
of 0.2 ml/min. 
Mass spectrometric (MS) detection 
was performed using a triple-quadruple 
mass spectrometer (Agilent Technologies, 
model LCMS-6410, Englewood, USA) 
with an electrospray ionization (ESI) 
interface. The ESI source was set at 
positive ionization mode. The [(M+H)
+
 
m/z 455.3] for methotrexate was selected 
as detecting ion, The MS operating 
conditions were optimized as follows: Ion 
spray voltage was set to 4000V, 
temperature of the ion transfer capillary 
was 25
o
C, Nebulizer gas (NEB) was 10, 
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and Curtain gas (CUR) was 8. The 
quantification was performed via  
peak-area. Data acquisition and processing 
were accomplished using Agilent LCMS 
solution software for LCMS-6410 system. 
Stock solutions of methotrexate were 
prepared in HPLC mobile phase at 
concentrations of 1 mg/ml and were stored 
at 4
0
C.Working solutions of methotrexate 
were prepared daily in HPLC mobile phase 
by appropriate dilution at 5.0, 10.0, 25.0, 
50.0, 100.0, 250.0, 500.0 ng/ml and 1.0, 
1.5 µg/ml. 
A 0.5 ml aliquot of the collected 
plasma sample from a human volunteer 
was pipetted into a 1 ml centrifuge tube 
0.5 ml acetonitrile was added and then was 
vortexes for 2 min. After centrifugation of 
the sample at 15400 rpm for 20 min, the 
organic layer was transferred to another 1 
ml centrifuge tube and an aliquot of 20 µl 
was injected into the LC–MS system. 
Proper volume of one of the  
above-mentioned working solutions to 
produce the standard curve point’s 
equivalent to 0.1, 0.2, 1, 5, 10, 20, 50 and 
100ng/ml of methotrexate were prepared 
and each sample was processed as 
described. Finally, the nominal known 
plasma concentrations were plotted against 
the corresponding peak areas to construct 
the standard curve. 
Quality control samples were prepared 
daily by spiking different samples of 0.5 
ml plasma each with proper volume of the 
corresponding standard solution to 
produce a final concentration equivalent to 
low level (0.2 ng/ml), middle level  
(20. ng/ml) and high level (100.0 ng/ml) of 
methotrexate. Then, the same procedures 
were carried out as described above. 
To evaluate the matrix effect on the 
ionization of analyses, 5 different 
concentration levels of methotrexate (0.1, 
0.2, 5, 10, and 100ng mL-1) were prepared 
in the drug-free blank plasma as ﬁve 
sample series using ﬁve different lots of 
the drug-free plasma and the samples were 
processed, as described, and injected into 
LC–MS. The same concentrations were 
prepared in mobile phase instead of 
plasma and analyzed for drug 
concentration using the same procedure. A 
comparison of the matrix effects of the 
two variants was made as an indicator of 
the method specificity. 
Standard curves of ten concentrations 
of methotrexate ranged 0.05–100ng/ml 
were assayed. Blank plasma samples were 
analyzed to ensure the lack of 
interferences but not used to construct the 
calibration function. The lower limitation 
of detection (LOD) and the lower 
limitation of quantification (LOQ) were 
determined as the concentrations with a 
signal-to-noise ratio of 4. 
In one run, three samples with 
concentrations of 0.2, 20, and 100 ng/ml 
(from high, middle, and low regions of the 
standard curve) were prepared in triplicate 
and analyzed by developed LC-Mass 
method. Then, the coefficient of variations 
(CV%) of the corresponding determined 
concentrations were calculated in each 
case. 
On three different runs, samples from 
upper, intermediate, and lower 
concentration regions used for 
construction of standard curve (the same 
as within-run variations test) were 
prepared and analyzed by  
LC-Mass method. Then, the corresponding 
CV% values were calculated. 
Three samples with concentrations of 
0.2, 20, and 100 ng/ml (from high, 
middle, and low regions of the standard 
curve) were prepared in triplicate and 
analyzed by developed LC-Mass method. 
Then, the ratio of the recorded peak 
heighted to the peak heights resulted from 
the direct injection of the aqueous 
solutions of methotrexate with the same 
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concentrations were determined as 
percentage in each case. 
To test the method repeatability,  
6 independent spiked plasma samples with 
a drug concentration of 5 ng/ml were 
prepared as described. A single injection 
of each preparation was made to LC/MS 
and the percentage of RSD between the 
results was determined as the repeatability 
of the method. 
On a different day to that of the 
repeatability study, a second analyst 
executed analysis of a further six samples 
prepared as described in repeatability test 
procedure. The analysis was carried out 
using fresh reagents and a different HPLC 
column. The percentage of RSD between 6 
measurements was determined along with 
the percentage of RSD between the total of 
12 measurements from the repeatability 
and intermediate precision tests. 
Mean results for the same sample 
analysis between our laboratory and two 
different test facilities were obtained and 
the percentage difference between content 
measurements was calculated using the 
equation:  
[(highest value-lowest value)/mean value] × 100. 
Three concentration levels of QC 
plasma samples were stored at the storage 
temperature (−20oC) for 24 h and thawed 
unassisted at room temperature. When 
completely thawed, the samples were 
refrozen for 24 h under the same 
conditions. The freeze-thaw Cycle was 
repeated twice, then the samples were 
tested after three freeze (−20oC)-thaw 
(room temperature) cycles. 
Three concentration levels of QC 
plasma samples were kept at room 
temperature for a period that exceeded the 
routine preparation time of samples 
(around 6 h). 
Three concentration levels of QC 
plasma samples kept at low temperature 
(−20oC) were studied for a period of 4 
weeks. 
The auto sampler stability was 
conducted reanalyzing extracted QC 
samples kept under the auto sampler 
conditions (4
o
C) for 12 h. 
A standard curve in each analytical 
run was used to calculate the concentration 
of methotrexate in the unknown samples in 
the run. It was prepared at the same time 
as the unknown samples in the same batch 
and analyzed in the middle of the run. The 
QC samples in 5 duplicates at three 
concentrations (0.2, 20 and 100ng/ml) 
were prepared and were analyzed with 
processed test samples at intervals per 
batch. 
 
RESULTS 
LC–MS/MS with positive ESI was 
selected to detect methotrexate in human 
plasma. A prominent fragment with  
455.3 m/z was observed in the production 
scan with positive ESI Fig 2. A. According 
to the mass scan spectrum, m/z of 455.3 
produced by the quasi molecule ion 
[M+H]
+
 of methotrexate was selected for 
monitoring. The selected-ion monitoring 
(SIM) (+) chromatograms extracted from 
supplemented plasma is depicted in Fig 2. 
E as shown, the retention times of 
methotrexate was 6.5 min. The total 
HPLC–MS analysis time was 7 min per 
sample. No interferences of the analytic 
were observed. Fig 2. B shows an HPLC 
chromatogram for a blank plasma sample 
indicating no endogenous peaks at the 
retention positions of methotrexate. All the 
ratios of the peak area resolved in blank 
sample compared with that of resolved in 
mobile phase. 
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(A) (B) 
(C) (D) 
(E) 
 
 
Figure 2: The SIM (+) chromatograms of methotrexate 
(A) Positive ion electrospray mass scan spectrum of: methotrexate; (B) blank plasma; (C) LOD (concentration of 
methotrexate=0.05 ng/ml); (D) LOQ (concentration of methotrexate=0.10ng/ml); (E) The SIM (+) chromatograms 
for Supplemented plasma (concentration of methotrexate=4 ng/ml). 
 
As it is clearly evident from the typical 
chromatograms of the developed method 
shown in Fig 2, there are no discernible 
interferences between the matrix factors and 
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the analyst. This, in turn, ensures obtaining 
reliable results from the method for 
determination of biological concentrations of 
methotrexate. 
The method produced linear responses 
throughout the methotrexate concentration 
range of 0.1-100ng/ml, which is suitable for 
intended purposes. A typical linear regression 
equation of the method was: y=1444.3,  
x=-16740, with x and y representing 
methotrexate concentration (in ng/ml) and 
peak height (in arbitrary units), respectively, 
and the regression coefficient (r) of 0.998. The 
lower limit of quantification for methotrexate 
was proved to be 0.1ng/ml and the lower limit 
of detection was 0.05 ng/ml (Fig 2).  
C shows the chromatogram of an extracted 
sample that contained 0.05 ng/ml (LOD) of 
methotrexate Fig 2. D shows the 
chromatogram of an extracted sample that 
contained 0.10 ng/ml (LOQ) of methotrexate. 
The within-run variations of the 
developed LC-Mass method as well as the 
corresponding absolute recoveries are shown 
in Table 1. These data clearly show that the 
developed method has an acceptable degree 
of repeatability and accuracy within an 
analytical run. 
 
Table 1: Within–run variations and accuracy of the LC-Mass method for quantitation of 
methotrexate (n=3) 
CV% Mean ± SD Measured 
Concentration (ng/ml) 
Sample 
Number 
Nominal Added 
Concentration (ng/ml) 
 
10 
 
0.20±0.02 
0.22 1  
0.2 0.18 2 
0.20 3 
 
0.32 
 
20.03±0.06) 
20.03 1  
20 19.97 2 
20.1 3 
 
0.82 
 
99.46±0.81 
100.40 1  
100 98.93 2 
99.05 3 
 
The between-run variations of the 
developed LC-Mass method as well as the 
corresponding absolute recoveries are shown 
in Table 2. As stated for the previous test, 
these data clearly show that the developed 
method has an acceptable degree of 
reproducibility and accuracy between 
different analytical runs. 
 
Table 2: Between–run variations and accuracy of the LC-Mass method for quantitation of 
methotrexate (n=3) 
CV% Mean ± SD Measured 
Concentration (ng/ml) 
Run Number Nominal Added 
Concentration (ng/ml) 
 
7.39 
 
0.2±0.01 
0.19 1  
0.2 0.21 2 
0.22 3 
 
4.62 
 
20.2±0.96 
20.07 1  
20 20.93 2 
19.08 3 
 
0.58 
 
99.65±0.58 
99.01 1  
100 99.80 2 
100.15 3 
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The extraction recovery determined for 
methotrexate was shown to be consistent, 
precise and reproducible. Data were shown 
below in Table 3. These data indicate that 
there is no significant matrix effect on the 
outputs of the assay method. 
 
Table 3: Relative recovery of methotrexate by the LC-Mass method (N=3) 
Nominal Added Concentration (ng/ml) Sample Number Percent Recovery (%) Mean ± SD CV% 
 
0.2 
1 98.15  
95.78±2.47 
 
2.58 2 93.21 
3 95.98 
 
20 
1 93.42  
94.67±1.58 
 
1.67 2 96.45 
3 94.15 
 
100 
1 91.60  
93.47±1.80 
 
1.93 2 95.21 
3 93.61 
 
The repeatability of the method is 
shown in Table 4. As shown, the method has 
a remarkable repeatability for the drug 
assessment in plasma. 
 
Table 4: Repeatability of the test results for spiked plasma containing 5 ng mL-1methotrexate 
Sample Peak area Mean ± SD CV% Retention time (min) Mean ± SD CV% 
1 2435432  
 
2435570 ± 3254.82 
 
 
0.133 
6.54  
 
6.64 ± 0.08 
 
 
1.31 
2 2431234 6.71 
3 2436578 6.77 
4 2432321 6.59 
5 2439087 6.58 
6 2438765 6.65 
 
The results of the intermediate precision 
test are shown in Table 5. As indicated, the 
developed method shows an acceptable 
intermediate precision for methotrexate assay. 
 
Table 5: Intermediate precision of the test results for spiked plasma containing  
5 ng mL-1methotrexate 
Sample Peak area Mean ± SD CV% Retention time (min) Mean ± SD CV% 
1 2435621  
 
2435071 ± 3230.52 
 
 
0.132 
6.73  
 
6.65 ± 0.06 
 
 
1.05 
2 2431234 6.55 
3 2435467 6.65 
4 2439087 6.71 
5 2437689 6.68 
6 2431327 6.59 
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The highest test result of the spiked 
plasma with 5 ng ml-1 methotrexate was 
2439087 and the lowest value was 
2431234 with the mean value of 2435071. 
Therefore, the percentage difference was 
0.32% which means a high reproducibility 
for the method. 
Table 6 summarizes the freeze and 
thaw stability, short term stability, long-
term stability and post-preparative stability 
data of methotrexate. All the results 
showed the stability behavior during these 
tests and there were no stability related 
problems during the samples routine 
analysis for the pharmacokinetic, 
bioavailability or bioequivalence studies. 
The stability of working solutions was 
tested at room temperature for 6 h. based 
on the results obtained; these working 
solutions were stable within 6 h. 
 
Table 6: Data showing stability of methotrexate in human plasma at different QC levels (n=5) 
Stability 0.2 (ng/ml) 20 (ng/ml) 100 (ng/ml) 
Short-term stability 91.98 95.43 95.09 
Freeze and thaw stability 94.42 97.14 93.76 
Long-term stability 95.66 92.87 93.89 
Post-preparative stability 92.87 91.87 91.81 
Data are presented as the percentage of the remaining concentration to the initial starting concentration. 
 
DISCUSSION 
Methotrexate is a folic acid antagonist 
drug which is used in patients with brain 
tumors. In addition to the clinical use of 
methotrexate, it is the subject of many 
preclinical investigations pertaining to its 
interesting pharmacological properties. 
Methotrexate as an anticancer drug, there 
has been numerous HPLC methods to 
determinate methotrexate in biological 
specimens. Most often these methods utilize 
solid phase extraction for sample cleanup 
with either UV or derivative fluorescence 
detection. Though, LC-MS is much more 
complicated technique as compared to in the 
past reported methods as it provides 
gangrenous information for all analyses 
which is very useful tool for the analysis of 
unknown mechanism of a mixture. To 
achieve this goal, it is highly desired to have 
a single, simple and inexpensive analytical 
method. In this study, we established a  
LC-MS method for simultaneously detecting 
MTX in human plasma. The outcomes 
showed that our LC-MS method completely 
satisfied these conditions as mentioned 
above. For this method, the plasma 
preparation for analysis consisted of a 
protein precipitation method. Considering 
the complex biological matrix of the 
samples to be analyzed and the nature of the 
method to be used for drug assessment, 
Protein precipitation was necessary and 
important because this technique can not 
only purify but also concentrate the sample. 
Methanol, per choleric acid and acetonetrile 
were all attempted and acetonetrile was finally 
adopted because of its high extraction 
efficiency and less interference. Precipitation 
with and without adding 0.1 MNaOH (100 µl) 
were both tried, and obvious differences were 
not observed. So, the precipitation using 
acetonetrile without adding 0.1 MNaOH was 
used at last. The validation tests on the 
developed method showed acceptable degree 
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of linearity, sensitivity, precision, accuracy 
and recovery for the method. 
 
CONCLUSION 
A sensitive, selective, accurate and 
precise HPLC method with selected ion 
monitoring by single quadruple mass 
spectrometer with ESI interface was 
developed and validated for determination 
of methotrexate in human plasma. This 
method offers several advantages such as a 
rapid and simple extraction scheme and a 
short chromatographic run time, which 
makes the method suitable for the analysis 
of large sample batches resulting from the 
study of methotrexate in human plasma. 
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